AERI - Aerie Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
12/30/2015
Total Revenue
59,687
24,181
0
0
0
Cost of Revenue
3,526
641
-
-
0
Gross Profit
56,161
23,540
-
-
0
Operating Expenses
Research Development
87,076
86,123
72,078
52,394
44,451
Selling General and Administrative
134,822
120,614
73,615
44,478
30,635
Total Operating Expenses
245,640
233,282
145,693
96,872
75,086
Operating Income or Loss
-189,479
-209,742
-145,693
-96,872
-75,086
Interest Expense
9,760
2,531
2,368
2,537
2,493
Total Other Income/Expenses Net
450
-23,722
-555
543
3,355
Income Before Tax
-196,065
-232,566
-146,863
-98,866
-74,224
Income Tax Expense
-90
3
-1,758
193
139
Income from Continuing Operations
-195,975
-232,569
-145,105
-99,059
-74,363
Net Income
-195,975
-232,569
-145,105
-99,059
-74,363
Net Income available to common shareholders
-195,975
-232,569
-145,105
-99,059
-74,363
Reported EPS
Basic
-
-5.58
-4.11
-3.40
-2.88
Diluted
-
-5.58
-4.11
-3.40
-2.88
Weighted average shares outstanding
Basic
-
41,664
35,324
29,136
25,781
Diluted
-
41,664
35,324
29,136
25,781
EBITDA
-
-227,593
-143,085
-95,359
-71,479